You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Where is the tirzepatide used in compounding coming from?
Eli Lilly and Company is the only lawful supplier of FDA-approved tirzepatide medications and does not provide tirzepatide active pharmaceutical ingredient (API) to compounding pharmacies or other manufacturers.
See important safety information, including boxed warning, in the attached prescribing information.
Where is the Tirzepatide Used in Compounding Coming From?
Eli Lilly and Company (Lilly) is the only lawful supplier of FDA-approved tirzepatide medicines—Mounjaro® and Zepbound®—and does not provide tirzepatide (the active ingredient in Mounjaro® and Zepbound®) to compounding pharmacies, med-spas, wellness centers, online retailers, or other manufacturers.1
Products claiming to be compounded tirzepatide, Mounjaro®, or Zepbound® are not subject to FDA approval, may not have the same safety, quality, and efficacy as FDA-approved drugs, and may expose patients to potentially serious health risks.1
For more information on counterfeit or compounded tirzepatide, you may visit https://www.lilly.com/safety/real-medicine.2
Enclosed Prescribing Information
Reference
1An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro® (tirzepatide) and Zepbound® (tirzepatide). Press release. Eli Lilly and Company; June 20, 2024. Accessed June 20, 2024. https://investor.lilly.com/news-releases/news-release-details/open-letter-eli-lilly-and-company-regarding-certain-practices
2Protect yourself against counterfeit, fake, and unsafe or untested compounded products. Eli Lilly and Company. Accessed July 17, 2024. https://www.lilly.com/safety/real-medicine
Date of Last Review: July 17, 2024